Mid-life racial discrimination in Black Americans tied to Alzheimer’s later on, study finds
By
Kristen Fischer
Apr 12, 2024
Racial discrimination during midlife is linked to Alzheimer’s disease, a new study finds.
Scientists say they’ve zeroed in on a cause of Alzheimer’s
By
Alicia Lasek
Dec 03, 2021
Researchers from the University of California, Riverside say they have uncovered a reason why some people with plaques and tangles in their brains do not develop Alzheimer’s disease.
Dementia signs, symptoms may be different for Latinos, researchers say
By
Alicia Lasek
May 27, 2021
Cultural practices and disease processes may explain why Latino adults with dementia experience faster functional decline and higher rates of depression and anxiety, investigators say.
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
COVID-19 patients face higher risk of neurodegenerative disorders: study
By
Alicia Lasek (f3)
Jul 01, 2022
People who test positive for COVID-19 are at an increased risk of Alzheimer’s disease, Parkinson’s disease and ischemic stroke, a large new study finds.
Most women unaware of their Alzheimer’s risk, Cleveland Clinic survey finds
By
Alicia Lasek (f3)
Jun 30, 2022
Fully 82% of U.S. women are unaware of their relatively high odds of developing Alzheimer’s disease. And most have not addressed key risk factors with a healthcare provider.
Specialty care is out of reach for most dementia patients: study
By
Alicia Lasek
Sep 04, 2019
Most dementia patients do not receive diagnosis or care from specialists, a new study has found. An “unspecified dementia” diagnosis is common.
Drug that targets Alzheimer’s inflammation approved for trial by FDA
By
Alicia Lasek
Feb 09, 2021
An experimental drug meant to treat the “type 3 diabetes” that some scientists believe triggers Alzheimer’s has been approved for a late-stage clinical trial.
FDA fast-tracked dementia drug with known harms, reporter says
By
Kristen Fischer
Aug 18, 2023
An article in The BMJ is sounding the alarm that the US Food and Drug Administration fast-tracked approval for the dementia drug Rexulti (brexpiprazole) — even though trials show the drug is harmful.
Medicare costs could rise by $5B annually with expanded Alzheimer’s drug coverage: study
By
Alicia Lasek
May 12, 2023
Medicare costs could rise by $2 to $5 billion a year if CMS expands its coverage for newly approved Alzheimer’s disease drug Leqembi (lecanemab), investigators say.